QUOTE AND NEWS
Benzinga  Aug 26  Comment 
Biotech analysts at Piper Jaffray stated in a note on Wednesday that "we are buyers on weakness" of select biotech names that boast strong enough balance sheets to "make it through" upcoming value-driving events. The analysts, led by Edward...
TheStreet.com  Aug 26  Comment 
NEW YORK (TheStreet) -- PACCAR Inc. stock was upgraded to "overweight" from a "neutral"at Piper Jaffray this morning. The firm also raised its price target to $68 from $65 on the stock. Shares fell from $62.48 on August 19 to $55.90 on...
Benzinga  Aug 25  Comment 
Shares of Priceline Group Inc (NASDAQ: PCLN) have dipped around 15 percent since its second-quarter print despite reporting numbers above Street estimates and issuing in-line guidance. Michael Olson of Piper Jaffray commented in a note on...
Benzinga  Aug 25  Comment 
Shares of VeriFone Systems, Inc. (NYSE: PAY) have declined almost 20 percent in the past three months, from its high of $38.93 in June. Michael J. Grondahl of Piper Jaffray upgraded the rating on VeriFone Systems from Neutral to Overweight,...
Benzinga  Aug 24  Comment 
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have risen over 132 percent, year to date, reaching a peak on August 17, of $36.39. Piper Jaffray’s Edward A. Tenthoff has upgraded Sarepta Therapeutics to Overweight, while raising the...
TheStreet.com  Aug 24  Comment 
NEW YORK (TheStreet) -- Bristol-Myers Squibb  stock was upgraded to "neutral" from "underweight" at Piper Jaffray on Monday. When the firm initiated coverage on the stock this June, it viewed the company as overvalued at about $65, but now...
TheStreet.com  Aug 24  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Abercrombie & Fitch was upgraded at Piper Jaffray to overweight from neutral. $27 price target. Company is leveraged to growing denim demand, Piper Jaffray said. AutoZone was upgraded at Bank of...
Benzinga  Aug 21  Comment 
Piper Jaffray analysts Nicole Miller Regan and Joshua C. Long traveled with Habit Restaurants Inc (NASDAQ: HABT)’s management – including CEO Russ Bendel and CFO Ira Fils – this week, and left feeling optimistic about the company’s...
Benzinga  Aug 18  Comment 
In a report published Tuesday, Piper Jaffray analyst Edward A. Tenthoff maintained an Underweight rating and price target of $30 on Seattle Genetics, Inc. (NASDAQ: SGEN). The company's ADCETRIS candidate has received approval for use in...





You may also be interested in articles related to Piper Jaffray Companies (PJC):
 




You have more usfuel info than the British had colonies pre-WWII.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki